Cathie Wood, known for early investments in innovative companies, has added a biotech stock to her portfolio. CRISPR Therapeutics, with its gene-editing technology and recent product approval, is poised for significant growth.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing